Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

(2011) Shyam Sundar et al.   LANCET

Combination therapy for visceral leishmaniasis

(2010) Johan van Griensven et al.   LANCET INFECTIOUS DISEASES

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study

(2010) Ahmed M. Musa et al.   PLoS Neglected Tropical Diseases

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial

(2010) Asrat Hailu et al.   PLoS Neglected Tropical Diseases

Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients

(2008) T. P. C. Dorlo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Treatment Approach in Indian Visceral Leishmaniasis: Single‐Dose Liposomal Amphotericin B Followed by Short‐Course Oral Miltefosine

(2008) Shyam Sundar et al.   CLINICAL INFECTIOUS DISEASES

Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography–tandem mass spectrometry

(2008) Thomas P.C. Dorlo et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES